Circulating Tumor Cell-Derived Pre-Clinical Models for Personalized Medicine

Area of Science:

• Oncology
• Cancer Research
• Translational Medicine

Background:

• Cancer metastasis is the primary cause of cancer-related death, often untreatable with current therapies.
• Effective preclinical models are essential for studying metastatic disease evolution and developing novel treatments.
• Circulating Tumor Cells (CTCs) offer a non-invasive liquid biopsy approach to capture tumor heterogeneity.

Purpose of the Study:

• To review and discuss the generation and utility of CTC-derived preclinical models.
• To highlight the challenges and strengths of various CTC-derived models, from 2D cultures to CDX models.
• To summarize recent advancements and applications of these models in cancer research.

Main Methods:

• Review of existing literature on CTC-derived models.
• Categorization of models based on complexity (e.g., 2D cultures, CTC-derived explants/CDX models).
• Analysis of studies utilizing these preclinical tools.

Main Results:

• CTCs enable the creation of diverse preclinical models reflecting tumor heterogeneity.
• CTC-derived models, including CDX models, provide valuable insights into spatial and temporal tumor evolution.
• These models facilitate the investigation of cancer biomarkers and therapeutic strategies.

Conclusions:

• CTC-derived models are powerful tools for advancing cancer research, particularly for metastatic disease.
• Continued development and application of these models are vital for improving patient outcomes.
• Understanding CTC heterogeneity through these models is key to personalized cancer therapy.